Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Intra-articular injection of monoiodoacetate induces diverse hip osteoarthritis in rats, depending on its dose

Open access

Abstract

Background: Monoiodoacetate (MIA)-induced arthritis models are used widely in osteoarthritis (OA) research to develop effective conservative treatments for hip OA, as an alternative to joint replacement surgery. In joint OA models, such as the MIA-induced knee OA model, various doses of MIA are utilized, depending on the purpose of the research. So far, only 2 mg of MIA has been used for MIA-induced hip OA research. We hypothesized that the amount of MIA should be adjusted according to the osteoarthritis model under investigation. We performed radiographic and histological evaluations in rats for hip OA models induced by different doses of MIA. Methods: One hundred and eighty right hips of six-week-old, male Sprague–Dawley rats (n = 30 rats per group) were treated with either a single intra-articular injection of various doses of MIA (0.25, 0.5, 1.0, 2.0, and 4.0 mg) dissolved in 25 μl of sterile saline (MIA group), or with 25 μl of sterile saline alone (Sham group). Radiographic and histological evaluations of the hip joint were performed at one, two, four, eight, and 12 weeks after administration (n = 6 rats per group per time point). Results: OA changes progressed from 1 week after administration in the 1.0-mg, 2.0-mg, and 4.0-mg MIA groups. The degree of OA changes increased as the dose of MIA increased. The 0.25-mg and 0.5-mg MIA groups presented fewer OA changes than the 2.0-mg and 4.0-mg MIA groups during the entire study period (up to 12 weeks). The administration of 0.25 mg and 0.5 mg of MIA-induced both radiographic and histological OA changes in a time-dependent manner, whereas more than 2 mg of MIA provoked end-stage OA at 8 weeks after injection. Absolute, dose-dependent histopathological OA changes were observed 4 weeks after MIA administration. Conclusions: Intra-articular MIA injection to the hip joints of rats induced diverse OA changes dose-dependently. Research for developing novel conservative treatments for hip OA and intractable pain should consider the pathological condition when determining the dose of MIA to be employed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12891-022-05454-y

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 KG grades at each time point. a–e The KL classification grades at each time point, based on the dose of MIA. At each time point, the KL grades in the 2.0-mg and 4.0-mg MIA groups were significantly higher than those in the 0.25-mg and 0.5-mg MIA groups. At 8 weeks after MIA injection, the KL grades approached 4 in the groups receiving 2 mg MIA or more. At 12 weeks, the KL grades reached 4 in the groups receiving more than 1 mg of MIA. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. *, p < 0.05; **, p < 0.01 (vs. 0.25-mg MIA group). §, p < 0.05; §§, p < 0.01 (vs. 0.5-mg MIA group). ¶, p < 0.05; ¶¶, p < 0.01 (vs. 1.0-mg MIA group). †, p < 0.05; ††, p < 0.01 (vs. 2.0-mg MIA group). Abbreviations: KL, Kellgren and Lawrence system; MIA, monoiodoacetate; SEM, standard error of the mean
Fig. 1 KG grades at each time point. a–e The KL classification grades at each time point, based on the dose of MIA. At each time point, the KL grades in the 2.0-mg and 4.0-mg MIA groups were significantly higher than those in the 0.25-mg and 0.5-mg MIA groups. At 8 weeks after MIA injection, the KL grades approached 4 in the groups receiving 2 mg MIA or more. At 12 weeks, the KL grades reached 4 in the groups receiving more than 1 mg of MIA. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. *, p < 0.05; **, p < 0.01 (vs. 0.25-mg MIA group). §, p < 0.05; §§, p < 0.01 (vs. 0.5-mg MIA group). ¶, p < 0.05; ¶¶, p < 0.01 (vs. 1.0-mg MIA group). †, p < 0.05; ††, p < 0.01 (vs. 2.0-mg MIA group). Abbreviations: KL, Kellgren and Lawrence system; MIA, monoiodoacetate; SEM, standard error of the meanCC BY · PubMed Central
Fig. 2 Radiography and histopathology of the hip. Radiography and histopathology of the hip in the Sham and MIA groups (0.25-mg, 0.5-mg, 1.0-mg, 2.0-mg, and 4.0-mg) 12 weeks after MIA administration. a–f Anteroposterior radiographs of the rat hip. g–l Hematoxylin and eosin-stained tissues. m–r Safranin O-stained tissues. As the MIA dose increased, OA changes progressed both radiologically and histologically. At concentrations of 0.5 mg MIA and higher, end-stage joint destruction was observed at 12 weeks. Abbreviations: MIA, monoiodoacetate; OA, osteoarthritis
Fig. 2 Radiography and histopathology of the hip. Radiography and histopathology of the hip in the Sham and MIA groups (0.25-mg, 0.5-mg, 1.0-mg, 2.0-mg, and 4.0-mg) 12 weeks after MIA administration. a–f Anteroposterior radiographs of the rat hip. g–l Hematoxylin and eosin-stained tissues. m–r Safranin O-stained tissues. As the MIA dose increased, OA changes progressed both radiologically and histologically. At concentrations of 0.5 mg MIA and higher, end-stage joint destruction was observed at 12 weeks. Abbreviations: MIA, monoiodoacetate; OA, osteoarthritisCC BY · PubMed Central
Fig. 3 KL grades, based on MIA dose. a-c KL grades increased in a time-dependent manner in the 0.25-mg, 0.5-mg, and 1.0-mg MIA groups. d–e However, in the 2-mg and 4-mg MIA groups, the KL grades reached a plateau 8 weeks after administration. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. *, p < 0.05; **, p < 0.01 (vs. 1 week group). §, p < 0.05; §§, p < 0.01 (vs. 2-week group); ¶¶, p < 0.01 (vs. four-week group). †, p < 0.05 (vs. eight-week group). Abbreviations: KL, Kellgren and Lawrence system; MIA, monoiodoacetate; SEM, standard error of the mean
Fig. 3 KL grades, based on MIA dose. a-c KL grades increased in a time-dependent manner in the 0.25-mg, 0.5-mg, and 1.0-mg MIA groups. d–e However, in the 2-mg and 4-mg MIA groups, the KL grades reached a plateau 8 weeks after administration. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. *, p < 0.05; **, p < 0.01 (vs. 1 week group). §, p < 0.05; §§, p < 0.01 (vs. 2-week group); ¶¶, p < 0.01 (vs. four-week group). †, p < 0.05 (vs. eight-week group). Abbreviations: KL, Kellgren and Lawrence system; MIA, monoiodoacetate; SEM, standard error of the meanCC BY · PubMed Central
Fig. 4 OARSI scores at each time point. a–b OARSI scores in the 4.0-mg MIA group at one and 2 weeks after MIA administration were significantly higher than those in 0.25-mg and 0.5-mg MIA groups. c In the fourth week, OARSI scores increased in a completely dose-dependent manner. d–e After the eighth week, there were no significant differences between the 1.0-mg, 2.0-mg, and 4.0-mg MIA groups. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. *, p < 0.05; **, p < 0.01 (vs. 0.25-mg MIA group). §, p < 0.05; §§, p < 0.01 (vs. 0.5-mg MIA group). ¶, p < 0.05; ¶¶, p < 0.01 (vs. 1.0-mg MIA group). ††, p < 0.01 (vs. 2.0-mg MIA group). Abbreviations: OARSI, Osteoarthritis Research Society International; MIA, monoiodoacetate; SEM, standard error of the mean
Fig. 4 OARSI scores at each time point. a–b OARSI scores in the 4.0-mg MIA group at one and 2 weeks after MIA administration were significantly higher than those in 0.25-mg and 0.5-mg MIA groups. c In the fourth week, OARSI scores increased in a completely dose-dependent manner. d–e After the eighth week, there were no significant differences between the 1.0-mg, 2.0-mg, and 4.0-mg MIA groups. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. *, p < 0.05; **, p < 0.01 (vs. 0.25-mg MIA group). §, p < 0.05; §§, p < 0.01 (vs. 0.5-mg MIA group). ¶, p < 0.05; ¶¶, p < 0.01 (vs. 1.0-mg MIA group). ††, p < 0.01 (vs. 2.0-mg MIA group). Abbreviations: OARSI, Osteoarthritis Research Society International; MIA, monoiodoacetate; SEM, standard error of the meanCC BY · PubMed Central
Fig. 5 OARSI scores, based on MIA dose. a–b With 0.25 mg and 0.5 mg of MIA, OARSI scores increased in a time-dependent manner, except for the score at 1–2 weeks in the 0.25-mg MIA group. c–d With 1.0 mg and 2.0 mg of MIA administration, time-dependent increases in OARSI scores were observed until 4 weeks after MIA injection. e With 4.0 mg of MIA administration, OARSI scores reached the maximum after 4 weeks. There were no significant differences among the four-week, eight-week, and 12-week groups. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. **, p < 0.01 (vs. 1 week group). §§, p < 0.01 (vs. two-week group). ¶¶, p < 0.01 (vs. four-week group). ††, p < 0.01 (vs. eight-week group). Abbreviations: OARSI, Osteoarthritis Research Society International; MIA, monoiodoacetate; SEM, standard error of the mean
Fig. 5 OARSI scores, based on MIA dose. a–b With 0.25 mg and 0.5 mg of MIA, OARSI scores increased in a time-dependent manner, except for the score at 1–2 weeks in the 0.25-mg MIA group. c–d With 1.0 mg and 2.0 mg of MIA administration, time-dependent increases in OARSI scores were observed until 4 weeks after MIA injection. e With 4.0 mg of MIA administration, OARSI scores reached the maximum after 4 weeks. There were no significant differences among the four-week, eight-week, and 12-week groups. Data are presented as mean ± SEM, n = 6 rats per group. Data were analyzed using two-way ANOVA, followed by the Tukey–Kramer method. **, p < 0.01 (vs. 1 week group). §§, p < 0.01 (vs. two-week group). ¶¶, p < 0.01 (vs. four-week group). ††, p < 0.01 (vs. eight-week group). Abbreviations: OARSI, Osteoarthritis Research Society International; MIA, monoiodoacetate; SEM, standard error of the meanCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 26

Metadata

Authors
Yoh, S., Kawarai, Y., Hagiwara, S., Orita, S., Nakamura, J., Miyamoto, S., Suzuki, T., Akazawa, T., Shiko, Y., Kawasaki, Y., & Ohtori, S.
Affiliations
  • Chiba University (JP)
  • Matsudo City Hospital (JP)
  • St. Marianna University School of Medicine (JP)
  • Chiba University Hospital (JP)
Corresponding author
Kawarai, Yuya
Venue
BMC Musculoskeletal Disorders
Published
2022-05-25
Volume
23
Issue
1
Pages
494-494
ISSN
1471-2474 (ISSN-L)
OpenAlex
W4281493637
Cited by
26
References
32
Citations by year
2026: 8 · 2025: 5 · 2024: 7 · 2023: 4 · 2022: 2
FWCI
3.26
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Musculoskeletal Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Nakatomi Foundation
  • Japan Society for the Promotion of Science (19K18487)
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Health Sciences › Medicine › Surgery › Hip disorders and treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone and Joint Diseases
Keywords
monoiodoacetate, hip osteoarthritis, intra-articular injection, animal models of osteoarthritis, radiographic osteoarthritis
MeSH terms
Animals, Disease Models, Animal, Humans, Injections, Intra-Articular, Male, Osteoarthritis, Hip, Rats, Sprague-Dawley, Iodoacetic Acid, Osteoarthritis, Knee, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intra-articular injection of monoiodoacetate induces diverse hip osteoarthritis in rats, depending on its dose. https://app.cochat.ai/papers/10.1186/s12891-022-05454-y
The paper
Yoh, S., Kawarai, Y., Hagiwara, S., Orita, S., Nakamura, J., Miyamoto, S., Suzuki, T., Akazawa, T., Shiko, Y., Kawasaki, Y., & Ohtori, S. (2022). Intra-articular injection of monoiodoacetate induces diverse hip osteoarthritis in rats, depending on its dose. BMC Musculoskeletal Disorders. https://doi.org/10.1186/s12891-022-05454-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.